Testing apremilast for genetic EBS with frequent blisters
Part of Genetic & congenital, Skin clinical trials.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child are at least 6 years old.
- You have a specific type of EBS caused by a change in the KRT5 or KRT14 genes (your doctor can confirm this).
- You get more than 3 new blisters each day on average.
- You will not use any topical creams or ointments on blisters unless the study doctor approves.
- You have not used certain oral or injected immune-suppressing medications in the last 30 to 60 days (study staff will check).
- You do not have an active blister infection that needs oral antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests a gel called Filsuvez on skin blisters and sores caused by epidermolysis bullosa simplex (EBS), a condition where skin is very fragile. The gel may help wounds heal faster and reduce pain.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.